Forte Biosciences Inc - Asset Resilience Ratio
Forte Biosciences Inc (FBRX) has an Asset Resilience Ratio of 0.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Forte Biosciences Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Forte Biosciences Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see FBRX asset base.
Liquid Assets Composition Over Time
This chart breaks down Forte Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Forte Biosciences Inc (FBRX) financial obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Forte Biosciences Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Forte Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Forte Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Forte Biosciences Inc (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Forte Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 58.68% | $36.12 Million | $61.56 Million | -5.88pp |
| 2023-12-31 | 64.56% | $25.16 Million | $38.98 Million | +10.94pp |
| 2018-12-31 | 53.62% | $55.27 Million | $103.08 Million | -3.72pp |
| 2017-12-31 | 57.34% | $52.79 Million | $92.07 Million | -15.46pp |
| 2016-12-31 | 72.80% | $25.73 Million | $35.35 Million | -8.84pp |
| 2015-12-31 | 81.64% | $50.76 Million | $62.17 Million | -- |
About Forte Biosciences Inc
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. … Read more